#Sweden #Stockholm #SciBase #Rights Issue #TO 2 Warrants

SciBase's Successful Rights Issue and Set-off Share Allocation

SciBase Holding AB, a prominent player in the medical technology sector, has made a significant announcement detailing the outcomes of its recent rights issue. This initiative, which was approved by the board on December 29, 2025, has garnered substantial interest from investors, with an impressive subscription rate of 96.4%. The rights issue, which allows current shareholders the option to purchase additional shares, achieved this milestone mainly due to the combination of 61.3% subscriptions supported by rights and 35.1% without such support.

Financial Implications

The company expects to raise approximately 79.9 million SEK before transaction costs, which are anticipated to be around 3.4 million SEK. This capital will enable SciBase to advance its strategic goals and further enhance its product offerings in dermatology.

Additionally, the board has completed a set-off share issue to manage debt incurred through their TO 2 warrant repurchase offer, initially announced on November 7, 2025. Accordingly, 209,075,476 shares were issued at a subscription price of 0.20 SEK per share, mirroring the rights issue price. Notably, all shares from this set-off issue have been fully subscribed and allocated.

Background on the Rights Issue

The subscription period for the rights issue ended on January 26, 2026, marking a pivotal moment for SciBase as it seeks to bolster financial stability. The allotment process for shares subscribed without rights will adhere to pre-established principles outlined in an information document published on January 9, 2026. Investors will receive notifications concerning their allotments, with payments required to follow the given guidelines.

The TO 2 offer proved highly successful, attracting acceptance from holders of 418,150,952 warrants, nearly 83.9% of the total. This proactive engagement saw a significant dilution of existing shares, reflecting the company's commitment to enhancing shareholder value while addressing liquidity and growth needs. After the rights and set-off issues, the total number of shares will rise to 1,022,530,000, accompanied by a substantial increase in the company’s share capital.

Market Conditions and Future Outlook

The board highlighted that the pricing for the shares in the set-off was reached after comprehensive consultations with financial advisors. Emphasis was placed on ensuring that the pricing aligns with market expectations, thereby reflecting genuine demand from investors.

Trading of the new shares is set to commence on the Nasdaq First North Growth Market around February 19, 2026, joining existing shares and allowing for greater liquidity in the market.

SciBase has been recognized for its innovative contributions to dermatology, specializing in early detection and management of skin health through advanced technologies such as Nevisense, which integrates AI and electrical impedance spectroscopy. The company's focus on patient-centric solutions aims to enhance diagnostic accuracy and improve clinical outcomes, further solidifying its reputation within the healthcare landscape.

Conclusion

In summary, the successful completion of the rights issue and the structured resolution regarding the TO 2 warrants exemplify SciBase’s robust strategy to enhance capital structure and investor confidence. As the company continues to develop pioneering diagnostic solutions, its commitment to improving patient health and optimizing resource use stands at the forefront of its operational objectives. Investors and stakeholders are encouraged to stay connected for forthcoming developments that could impact the company’s trajectory in the rapidly evolving healthcare market.

For further inquiries, you can contact:

• - Jesper Høiland, Chairman: +45 612 207 30
• - Michael Colérus, CFO: +46 70 341 34 72

Stay updated on investments and corporate news by following SciBase's communications on their official channels.